One-hour special: Meet the next big thing in obesity

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Arvid Söderhall, CEO at Empros Pharma.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Arvid, covering:

• The personal story of a pediatrician treating an obese child that led to the creation of Empros Pharma and its lead asset
• The 10-year journey from an idea to a successful Phase IIb trial... and what it felt like to reach the magic milestone
• Critical characteristics required for a small pharma leader, and why CEOs stand and fall with their data
• The ins and outs of a CDMO selection process for Phase 3 trials and the commercial launch for a global drug to complement GLP-1 products
• How the investor climate has changed in the last 1-2 years... and how it has it turned upside down in the hot obesity space

Arvid joined Empros as a project manager in 2013, during the company’s foundational phase, before the EMP16 project was named. He quickly ascended to CEO, steering Empros to prioritize its founders and inventors while leveraging a strong network of contacts and leading Empros to a phase 3-ready project that surpassed initial expectations.

He holds a Ph.D. in Physical Chemistry with a specialization in Computational Chemistry. He then completed a postdoctoral fellowship in Berlin, marking his first engagement with the pharma industry and filing a first patent, introducing a foray into biotech entrepreneurship. Subsequently, Arvid worked at Stockholm-based biotech ‘Sidec,’ focusing on cryo-electron microscopy of proteins. Despite the premature technology leading to Sidec’s closure, the foundational concept later earned a Nobel Prize, underscoring the importance of timing in innovation.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.